ARTICLE | Distillery Therapeutics
Cancer
February 28, 2017 11:51 PM UTC
Cell culture studies suggest activation of CD95 in combination with KRAS or HDAC inhibition could treat KRAS-expressing non-small cell lung cancer (NSCLC). In a human NSCLC cell line harboring an onco...
BCIQ Company Profiles